University of California, Los Angeles |
Donald Kohn |
Quest - Discovery Stage Research Projects |
Hematopoietic Stem Cell Gene Therapy for X-linked Agammaglobulinemia |
$219,230 |
University of California, Los Angeles |
Stanley Carmichael |
Quest - Discovery Stage Research Projects |
Human-induced pluripotent stem cell-derived glial enriched progenitors to treat white matter stroke and vascular dementia. |
$250,000 |
University of California, Los Angeles |
Lili Yang |
Discovery Research Projects |
Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells |
$250,000 |
University of California, Los Angeles |
Song Li |
Discovery Research Projects |
Biomaterial vaccine to enhance the formation of SARS-CoV-2-specific T memory stem cells |
$149,916 |
University of California, Los Angeles |
Vaithilingaraja Arumugaswami |
Therapeutic Translational Research Projects |
COVID-19 Antiviral Therapy to Block Direct Cell Injury and Associated Tissue Damage |
$349,999 |
University of California, Los Angeles |
Caroline Kuo |
Progression Award - Discovery Stage Research Projects |
Evaluation of Gene Therapy Approaches for Autosomal Recessive Hyper IgE Syndrome Due to Mutations in DOCK8 |
$234,000 |
University of California, Los Angeles |
Brigitte Gomperts |
Discovery Research Projects |
Identifying a lead compound for COVID19 using high throughput screening with lung stem cell organoids |
$149,998 |
University of California, Los Angeles |
Gay Crooks |
Discovery Research Projects |
Stem cell-based rapid identification of SARS-CoV-2 T cell epitopes and T cell receptors for therapeutic use |
$126,692 |
University of California, Los Angeles |
Sophie Deng |
Clinical Trial Stage Projects |
Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
University of California, Los Angeles |
Caroline Kuo |
Therapeutic Translational Research Projects |
Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome |
$4,896,628 |
University of California, Los Angeles |
Yvonne Chen |
Therapeutic Translational Research Projects |
BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma |
$3,176,805 |
University of California, Los Angeles |
Theodore Nowicki |
Clinical Trial Stage Projects |
Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors |
$4,693,839 |
University of California, Los Angeles |
Steven Schwartz |
Therapeutic Translational Research Projects |
Clinical Translation of Autologous Regenerative Cell Therapy for Blindness |
$5,068,026 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
University of California, Los Angeles |
Steven Dubinett |
Clinical Trial Stage Projects |
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
University of California, Los Angeles |
John Adams |
Conference - The 2018 Alpha Stem Cell Clinic Annual Symposium |
Delivery of Stem Cell Therapeutics to Patients |
$60,000 |
University of California, Los Angeles |
Scott Kitchen |
Quest - Discovery Stage Research Projects |
Engineering Lifelong Cellular Immunity to HIV |
$1,701,178 |
University of California, Los Angeles |
April Pyle |
Quest - Discovery Stage Research Projects |
Identification and Generation of Long Term Repopulating Human Muscle Stem Cells from Human Pluripotent Stem Cells |
$2,148,519 |
University of California, Los Angeles |
Stanley Carmichael |
Quest - Discovery Stage Research Projects |
iPS Glial Therapy for White Matter Stroke and Vascular Dementia |
$2,096,095 |
University of California, Los Angeles |
Alireza Moshaverinia |
Inception - Discovery Stage Research Projects |
Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration |
$194,483 |
University of California, Los Angeles |
Caroline Kuo |
Quest - Discovery Stage Research Projects |
Targeted Gene Editing in the Treatment of X-Linked Hyper-IgM Syndrome |
$1,512,333 |
University of California, Los Angeles |
Gay Crooks |
Quest - Discovery Stage Research Projects |
Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
University of California, Los Angeles |
Vaithilingaraja Arumugaswami |
Quest - Discovery Stage Research Projects |
Immunization strategies to prevent Zika viral congenital eye and brain disease |
$2,128,867 |
University of California, Los Angeles |
Song Li |
Conference II |
The 18th Annual UC System-Wide Bioengineering Symposium |
$25,000 |
University of California, Los Angeles |
John Chute |
Quest - Discovery Stage Research Projects |
Protein tyrosine phosphatase - sigma inhibitors for hematopoietic regeneration |
$2,116,708 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$10,156,925 |
University of California, Los Angeles |
April Pyle |
Quest - Discovery Stage Research Projects |
CRISPR/Cas9 nanoparticle enabled therapy for Duchenne Muscular Dystrophy in muscle stem cells |
$2,150,400 |
University of California, Los Angeles |
Sophie Deng |
Late Stage Preclinical Projects |
Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
University of California, Los Angeles |
Brigitte Gomperts |
Conference - Lung Regenerative Medicine Workshop |
Stem Cells for Lung Diseases - Overcoming Barriers to Find New Therapies |
$44,548 |
University of California, Los Angeles |
Stanley Carmichael |
Inception - Discovery Stage Research Projects |
iPS-Interneuron Transplantation for Neural Repair after Stroke |
$229,396 |
University of California, Los Angeles |
Arjun Deb |
Inception - Discovery Stage Research Projects |
Targeting progenitors in scar tissue to reduce chronic scar burden |
$230,400 |
University of California, Los Angeles |
Bennett Novitch |
Inception - Discovery Stage Research Projects |
Organoid Modeling of Human Cortical Microcircuits |
$208,916 |
University of California, Los Angeles |
April Pyle |
Inception - Discovery Stage Research Projects |
Novel Platforms to Enhance In Vivo Delivery of Skeletal Muscle Progenitor Cells from Human Pluripotent Stem Cells |
$230,400 |
University of California, Los Angeles |
Owen Witte |
Inception - Discovery Stage Research Projects |
Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
University of California, Los Angeles |
Peter Butler |
Therapeutic Translational Research Projects |
Personalized Cell Therapy for Diabetes |
$1,494,896 |
University of California, Los Angeles |
Lili Yang |
Therapeutic Translational Research Projects |
Stem Cell-Based iNKT Cell Therapy for Cancer |
$6,956,775 |
University of California, Los Angeles |
Donald Kohn |
Conference II |
Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop |
$29,807 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease |
$7,083,364 |
University of California, Los Angeles |
Hanna Mikkola |
Tools and Technologies III |
A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells |
$1,382,400 |
University of California, Los Angeles |
James Dunn |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$1,044,423 |
University of California, Los Angeles |
Carla Koehler |
Tools and Technologies III |
A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs |
$1,283,900 |
University of California, Los Angeles |
Leif Havton |
Tools and Technologies III |
Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases |
$1,308,711 |
University of California, Los Angeles |
John Adams |
Alpha Stem Cell Clinics |
UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium |
$8,000,000 |
University of California, Los Angeles |
John Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
University of California, Los Angeles |
Lili Yang |
Basic Biology V |
Differentiation of Human Hematopoietic Stem Cells into iNKT Cells |
$614,400 |
University of California, Los Angeles |
Denis Evseenko |
Basic Biology V |
Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes |
$411,330 |
University of California, Los Angeles |
Bennett Novitch |
Basic Biology V |
In vitro modeling of human motor neuron disease |
$1,148,758 |
University of California, Los Angeles |
Samantha Butler |
Basic Biology V |
Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate |
$515,730 |
University of California, Los Angeles |
Donald Kohn |
Disease Team Therapy Development III |
Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease |
$13,145,465 |
University of California, Los Angeles |
Dennis Slamon |
Disease Team Therapy Development III |
A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors |
$5,683,693 |
University of California, Los Angeles |
Dana Jones |
Conference |
7th CA/HSCI Junior PI Conference: Stem Cells 2.0 |
$2,500 |
University of California, Los Angeles |
Donald Kohn |
Early Translational IV |
Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells |
$1,651,884 |
University of California, Los Angeles |
Gerald Lipshutz |
Early Translational IV |
Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders |
$1,801,629 |
University of California, Los Angeles |
Robert Reiter |
Early Translational IV |
Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells |
$4,075,668 |
University of California, Los Angeles |
Zack Jerome |
Early Translational IV |
Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection |
$4,925,166 |
University of California, Los Angeles |
Brigitte Gomperts |
Tissue Collection for Disease Modeling |
Using human induced pluripotent stem cells to improve our understanding of Idiopathic Pulmonary Fibrosis |
$811,231 |
University of California, Los Angeles |
Tatiana Segura |
Conference |
2013 Materials Research Society (MRS) Spring Meeting Symposium
"Design of Cell Instructive Materials" |
$4,000 |
University of California, Los Angeles |
Ali Nsair |
New Faculty Physician Scientist |
Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. |
$2,316,894 |
University of California, Los Angeles |
Reza Ardehali |
New Faculty Physician Scientist |
Preclinical evaluation of human embryonic stem cell-derived cardiovascular progenitors in a large animal model |
$2,930,388 |
University of California, Los Angeles |
Kathrin Plath |
Basic Biology IV |
Understanding the status of the X chromosomes in human ESCs and preimplantation embryos |
$1,382,400 |
University of California, Los Angeles |
Owen Witte |
Basic Biology IV |
Trop2 dependent and independent mechanisms of self-renewal in human cancer stem cells |
$1,254,960 |
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Development - Research |
Genetic Re-programming of Stem Cells to Fight Cancer |
$14,144,221 |
University of California, Los Angeles |
Stanley Nelson |
Early Translational from Disease Team Conversion |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$1,823,545 |
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Planning I |
Genetic Re-programming of Stem Cells to Fight Cancer |
$97,785 |
University of California, Los Angeles |
Stanley Nelson |
Disease Team Therapy Planning I |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$68,947 |
University of California, Los Angeles |
Martina Wiedau-Pazos |
Conference |
California ALS Summit 2011 |
$13,300 |
University of California, Los Angeles |
Adele Rennie |
Patent Assistance Fund Awards |
Patent Assistance Fund - UCLA |
$84,973 |
University of California, Los Angeles |
Ali Nsair |
Basic Biology III |
Characterization and Engineering of the Cardiac Stem Cell Niche |
$1,127,741 |
University of California, Los Angeles |
Kathrin Plath |
Basic Biology III |
Discovery of mechanisms that control epigenetic states in human reprogramming and pluripotent cells |
$1,364,598 |
University of California, Los Angeles |
William Lowry |
Basic Biology III |
Molecular determinants of accurate differentiation from human pluripotent stem cells |
$677,115 |
University of California, Los Angeles |
Shuo Lin |
Basic Biology III |
Etsrp/ER71 mediated stem cell differentiation into vascular lineage |
$1,378,781 |
University of California, Los Angeles |
Gay Crooks |
Basic Biology III |
Forming the Hematopoietic Niche from Human Pluripotent Stem Cells |
$1,252,857 |
University of California, Los Angeles |
Yi Sun |
Basic Biology III |
Studying neurotransmission of normal and diseased human ES cell-derived neurons in vivo |
$1,382,400 |
University of California, Los Angeles |
Stanley Carmichael |
Tools and Technologies II |
Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke |
$1,825,613 |
University of California, Los Angeles |
Richard Gatti |
Tools and Technologies II |
Use of hiPSCs to develop lead compounds for the treatment of genetic diseases |
$1,833,054 |
University of California, Los Angeles |
Martin Martin |
Tools and Technologies II |
Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders |
$1,783,250 |
University of California, Los Angeles |
Irvin Chen |
Conference |
Stem Cells: A New Avenue of HIV Research and New Approaches to HIV Treatment |
$24,456 |
University of California, Los Angeles |
Sophie Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$1,524,947 |
University of California, Los Angeles |
Bruno Peault |
Early Translational II |
Harnessing native fat-residing stem cells for bone regeneration |
$5,359,076 |
University of California, Los Angeles |
Leif Havton |
Early Translational II |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$75,628 |
University of California, Los Angeles |
Sophie Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$697,507 |
University of California, Los Angeles |
Noriyuki Kasahara |
Early Translational II |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,340,625 |
University of California, Los Angeles |
Gay Crooks |
Transplantation Immunology |
Engineering Thymic Regeneration to Induce Tolerance |
$1,235,445 |
University of California, Los Angeles |
Douglas Black |
Basic Biology II |
Programs of alternative splicing regulation by polypyrimidine tract binding protein |
$1,344,562 |
University of California, Los Angeles |
Yong Kim |
Basic Biology II |
Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells |
$1,259,371 |
University of California, Los Angeles |
Benhur Lee |
Basic Biology II |
The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation |
$1,371,936 |
University of California, Los Angeles |
Dennis Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
University of California, Los Angeles |
Irvin Chen |
Early Translational from Disease Team Conversion |
Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. |
$1,505,000 |
University of California, Los Angeles |
Donald Kohn |
Disease Team Research I |
Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
University of California, Los Angeles |
Irvin Chen |
Disease Team Research I |
HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
University of California, Los Angeles |
Robb Maclellan |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
University of California, Los Angeles |
Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
University of California, Los Angeles |
Bennett Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,229,922 |
University of California, Los Angeles |
Michael Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
University of California, Los Angeles |
Gabriel Travis |
Early Translational I |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
University of California, Los Angeles |
Kenneth Dorshkind |
Research Training II |
UCLA CIRM Research Training Program II |
$7,790,488 |
University of California, Los Angeles |
Hsian-Rong Tseng |
Tools and Technologies I |
Microfluidic Platform for Screening Chemically Defined Conditions that Facilitate Clonal Expansion of Human Pluripotent Stem Cells |
$914,096 |
University of California, Los Angeles |
Michael Phelps |
Tools and Technologies I |
Novel Tools and Technologies for Translational PET Imaging of Cell-based Therapies |
$914,039 |
University of California, Los Angeles |
Antoni Ribas |
New Faculty II |
Stem Cells for Immune System Regeneration to Fight Cancer |
$3,072,000 |
University of California, Los Angeles |
Brigitte Gomperts |
New Faculty II |
Stem Cells in Lung Cancer |
$2,381,572 |